4D Molecular Therapeutics (FDMT) Profit After Tax: 2020-2025
Historic Profit After Tax for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Sep 2025 value amounting to -$56.9 million.
- 4D Molecular Therapeutics' Profit After Tax fell 29.73% to -$56.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$209.2 million, marking a year-over-year decrease of 45.79%. This contributed to the annual value of -$160.9 million for FY2024, which is 59.53% down from last year.
- Latest data reveals that 4D Molecular Therapeutics reported Profit After Tax of -$56.9 million as of Q3 2025, which was down 4.06% from -$54.7 million recorded in Q2 2025.
- In the past 5 years, 4D Molecular Therapeutics' Profit After Tax registered a high of -$7.6 million during Q2 2021, and its lowest value of -$56.9 million during Q3 2025.
- In the last 3 years, 4D Molecular Therapeutics' Profit After Tax had a median value of -$35.0 million in 2024 and averaged -$38.3 million.
- Its Profit After Tax has fluctuated over the past 5 years, first spiked by 60.08% in 2023, then slumped by 327.49% in 2024.
- 4D Molecular Therapeutics' Profit After Tax (Quarterly) stood at -$25.1 million in 2021, then declined by 9.15% to -$27.4 million in 2022, then decreased by 17.91% to -$32.3 million in 2023, then slumped by 53.86% to -$49.7 million in 2024, then decreased by 29.73% to -$56.9 million in 2025.
- Its Profit After Tax stands at -$56.9 million for Q3 2025, versus -$54.7 million for Q2 2025 and -$48.0 million for Q1 2025.